clinical trial · NCT04458259
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Neoplasm MetastasisPF-07265807SasanlimabAxitinib
brief summary
A First-in-Human Pharmacokinetic, Safety, and Tolerability Study of PF-07265807 as Monotherapy and in Combination in Participants with Advanced or Metastatic Solid Tumors
started
Sep 24, 2020
primary completion
Nov 15, 2024
completion
Nov 15, 2024
last updated
Jun 4, 2026
official title
A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE-FINDING, PHARMACOKINETIC, SAFETY AND TOLERABILITY STUDY OF PF 07265807 IN PARTICIPANTS WITH SELECTED ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol